Waiv, a Paris-based company, announced a $33 million financing round. The financing round is co-led by OTB Ventures and Alpha Intelligence Capital (AIC), with participation from Serena Data Ventures, Karista, and SistaFund. Waiv is spinning out from Owkin, where its team previously operated as Owkin Dx.
The company is building AI-native precision tests for oncology using digital histopathology and multimodal clinical data. Waiv's products include RlapsRisk BC, MSIntuit Suite, and BRCAura. Waiv has partnerships with global life science leaders, including an AI gBRCA pre-screen test for breast cancer (BRCAura) and a collaboration with MSD for AI-based identification of an MSI-enriched population.
Precision medicine only works when patients can be reliably matched to the therapies most likely to benefit them. This remains very complex to achieve. Waiv brings the scalability and speed of AI to oncology testing, while enabling drug developers to access insights that were previously out of reach. Our goal is to make accurate AI-enabled precision testing the global standard.
Specific timelines or milestones for Waiv's global deployment of its AI precision testing platform have not been disclosed. In another development, AMI, co-founded by Turing Award winner Yann LeCun, secured 890 million euros in funding. AMI was already valued at three billion euros before this funding round.
Investors in AMI include Nvidia, Samsung, Toyota, Eric Schmidt, and Jeff Bezos. AMI aims to develop AI systems that understand the physical world more comprehensively, moving beyond large language models. AMI's research builds on the JEPA project initiated at Meta.
Waiv is bringing a level of technological advancement and maturity that oncology has been waiting for. Their AI tech stack, built on advanced foundation models, c
AMI plans intensive R&D over the next twelve months, followed by industrial collaborations. AMI is headquartered in Paris with offices in New York, Singapore, and Montreal. Alexandre Lebrun is the CEO of AMI, and Yann LeCun is the non-executive chairman.
AMI Labs is developing world models to achieve more advanced AI. How AMI's approach to world models differs technically from existing large language models remains unclear. Meanwhile, sources say Swedish AI company Agaton raised 90 million Swedish kronor.
The decisions concerning the uses of artificial intelligence must fall to civil society and its democratic institutions, and not solely to researchers or companies in the sector.
Agaton is backed by Inception Fund and King founder Sebastian Knutsson, sources say. What specific applications or products Agaton develops with its AI technology has not been specified. Separately, sources say Jan Erik Solem, founder of Mapillary, has a new company that aims to make robots work together.
Jan Erik Solem's company raised 85 million Swedish kronor, sources say. The name of Jan Erik Solem's new company focused on robot collaboration is unknown, and details about other investors in the funding rounds for Solem's company and Agaton beyond the mentioned amounts have not been revealed.